{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:09Z","timestamp":1791580809946,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jns.2022.120459","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T12:54:53Z","timestamp":1665752093000},"page":"120459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review"],"prefix":"10.1016","volume":"443","author":[{"given":"Kanika","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tolaymat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxuyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elkhooly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anek","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Kakara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitiz","family":"Sriwastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2022.120459_bb0005","series-title":"Neuroradiology","first-page":"103","article-title":"12 - Progressive Multifocal Leukoencephalopathy","author":"Paul","year":"2019"},{"issue":"4","key":"10.1016\/j.jns.2022.120459_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120459_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rmv.710","article-title":"Progressive multifocal leukoencephalopathy: clinical and molecular aspects","volume":"22","author":"Tavazzi","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.jns.2022.120459_bb0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","article-title":"Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review","volume":"8","author":"Fournier","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2022.120459_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000311014","article-title":"Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005","volume":"35","author":"Christensen","year":"2010","journal-title":"Neuroepidemiology."},{"issue":"12","key":"10.1016\/j.jns.2022.120459_bb0030","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jns.2022.120459_bb0035","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/598335","article-title":"Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study","volume":"48","author":"Khanna","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jns.2022.120459_bb0040","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.21564","article-title":"Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases","volume":"64","author":"Bharat","year":"2012","journal-title":"Arthritis Care Res."},{"issue":"4","key":"10.1016\/j.jns.2022.120459_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729901","article-title":"Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review","volume":"24","author":"Bohra","year":"2017","journal-title":"Cancer Control"},{"issue":"40","key":"10.1016\/j.jns.2022.120459_bb0050","article-title":"Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica","volume":"5","author":"Paz","year":"2018","journal-title":"Epidemiol. Health."},{"key":"10.1016\/j.jns.2022.120459_bb0055","doi-asserted-by":"crossref","first-page":"577721","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","volume":"360","author":"Sriwastava","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2022.120459_bb0065","series-title":"TYSABRI\u00ae (natalizumab) - PML Incidence in Patients Receiving Natalizumab","year":"2022"},{"key":"10.1016\/j.jns.2022.120459_bb0070","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","author":"Jordan","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2022.120459_bb0075","article-title":"Update on the risk estimates of progressive multifocal leukoencephalopathy related to fingolimod","author":"Fox","year":"2020","journal-title":"MS Virtual"},{"issue":"20","key":"10.1016\/j.jns.2022.120459_bb0080","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2022.120459_bb0085","unstructured":"TECFIDERA\u00ae (dimethyl fumarate) and VUMERITY\u00ae (diroximel fumarate) -Progressive Multifocal Leukoencephalopathy Summary. Summary. (Accessed July 2022). https:\/\/biogen-inscite.veevavault.com\/ui\/approved_viewer?token=5266-2af56df6-539c-4c7b-8f74-aebc11d741fd& dns=biogen-inscite.veevavault.com."},{"key":"10.1016\/j.jns.2022.120459_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101416","article-title":"Role of B cells and antibodies in multiple sclerosis","volume":"36","author":"Wanleenuwat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.jns.2022.120459_bb0100","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/ijms18102048","article-title":"Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function","volume":"18","author":"Lehmann-Horn","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2022.120459_bb0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr. Dir. Autoimmun."},{"issue":"7","key":"10.1016\/j.jns.2022.120459_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.jns.2022.120459_bb0115","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2019","journal-title":"Mult. Scler."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120459_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jns.2015.04.010","article-title":"Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis","volume":"353","author":"Asztely","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2022.120459_bb0130","first-page":"323","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.jns.2022.120459_bb0140","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with Ocrelizumab monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2022.120459_bb0145","series-title":"Poster Session Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm","article-title":"Cases reported as progressive multifocal leukoencephalopathy in Ocrelizumab-treated patients with multiple sclerosis","author":"Clifford","year":"2019"},{"issue":"4","key":"10.1016\/j.jns.2022.120459_bb0160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3324\/haematol.2014.118158","article-title":"Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia","volume":"100","author":"Moreno","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jns.2022.120459_bb0165","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2014.07.013","article-title":"Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program","volume":"15","author":"Dupuis","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.jns.2022.120459_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13256-020-2360-9","article-title":"Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report","volume":"14","author":"Forryan","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.jns.2022.120459_bb0175","series-title":"Arzerra [PackageInsert]","year":"2016"},{"issue":"8","key":"10.1016\/j.jns.2022.120459_bb0180","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/1352458519832259","article-title":"Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy","volume":"25","author":"Gerevini","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2022.120459_bb0185","series-title":"Oral Presentation Dr. Steinman ULTIMATE I-II","author":"ECTRIMS","year":"2021"},{"issue":"11","key":"10.1016\/j.jns.2022.120459_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.jns.2022.120459_bb0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s11481-019-09877-8","article-title":"Host-immune interactions in JC virus reactivation and development of progressive multifocal leukoencephalopathy (PML)","volume":"14","author":"Khalili","year":"2019","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"10","key":"10.1016\/j.jns.2022.120459_bb0200","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/nn1005-1275","article-title":"Natalizumab and PML","volume":"8","author":"Ransohoff","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"11","key":"10.1016\/j.jns.2022.120459_bb0205","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2165\/00023210-200519110-00002","article-title":"The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications","volume":"19","author":"Sheremata","year":"2005","journal-title":"CNS Drugs."},{"issue":"2","key":"10.1016\/j.jns.2022.120459_bb0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.jns.2022.120459_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.jns.2022.120459_bb0220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult. Scler."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:46Z","timestamp":1758383986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":38,"alternative-id":["S0022510X22003215"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120459","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120459"}}